Clinical trials: Advanced Esophageal Cancer
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Locally Advanced Unresectable Gastric Adenocarcinoma
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.
- Trial name
- NCT05974059
- Testing
- Oxaliplatin, Capecitabine, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Carcinoma, Radiotherapy
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.
- Conditions
- Esophageal Carcinoma, Radiotherapy, Immunotherapy
- Trial name
- NCT06964568
- Testing
- PD-1 inhibitor, Unlimited radiotherapy, TP regimen
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Fudan University
Esophagus Cancer
Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.
To compare the treatment of gullet cancer with radiotherapy alone and assess the advantage and toxicity of adding chemotherapy. The hypothesis to be tested is as follows: That the addition of chemotherapy to a short course of…
- Trial name
- NCT00193882
- Testing
- Cisplatin, Radiotherapy, 5-Fluorouracil
- Where
- 25 sites in Australia, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Esophageal Squamous Cell Carcinoma, PD-1 Inhibitor
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
200 patients with advanced esophageal cancer who received PD-1 monoclonal antibody treatment would be enrolled in this study. Changes in peripheral blood immune cells before and after treatment would be recorded and used for…
- Trial name
- NCT05392413
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Esophageal Cancer
High Dose PET/CT-guided Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer
To assess the efficacy and feasibility of high-dose intensity-modulated radiotherapy with concurrent weekly paclitaxel and cisplatin for patients with locaregionally esophageal cancer
- Trial name
- NCT03936179
- Testing
- high dose radiation therapy with concurrent chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma
Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer
GastroPET is a prospective, multicenter, non-randomized interventional study evaluating sequential FDG-PET as an early biomarker to guide preoperative treatment in patients with locally advanced resectable oesophago-gastric…
- Conditions
- Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GastroPET (NCT07791329)
- Testing
- FDG-PET
- Where
- Czechia
- Volunteers
- 144 people
- Sponsor
- Masaryk Memorial Cancer Institute
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Esophageal Squamous Cell Cancer
Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT07769866
- Testing
- Induction chemo-immunotherapy, Concurrent chemoradiotherapy (cCRT), maintenance immunotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- RenJi Hospital
Esophageal Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced or recurrent esophageal cancer who have completed the previous Phase 2 study (CA139-540) and who should continue on therapy with…
- Trial name
- NCT00971841
- Testing
- Paclitaxel
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Gastric Cancer, Esophageal Cancer
Perception Prognosis, Goals of Treatment, and Communication
The purpose of this research study is to assess what the participant understands about their illness, prognosis, the goals of the cancer treatment and their communication with their oncology providers.
- Conditions
- Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT01401894
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy…
- Trial name
- NCT06912074
- Testing
- Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Sun Yat-sen University
Esophageal Carcinoma
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05476380
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Colorectal Neoplasms, Throat Cancer
Fecal Screening Assay for Taiwanese Population
Fecal occult blood test (FOBT) is a convenient tool for the screening of asymptomatic gastrointestinal (GI) bleeding while 「guaiac-based fecal occult test (G-FOBT) 」 is increasingly replaced by the use of an 「immunochemical-based…
- Conditions
- Advanced Colorectal Neoplasms, Throat Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01341197
- Testing
- Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test
- Where
- Taiwan
- Volunteers
- 3,172 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
ESCC
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer
A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC
- Trial name
- TC (NCT04471480)
- Testing
- TC/PD-1 inhibitor/anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Dong Wang
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Neuroendocrine Carcinoma
Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
The study will be conducted to compare the safety and efficacy of irinotecan combined with cisplatin (IP regimen) and etoposide combined with cisplatin (EP regimen) in advanced or metastatic gastrointestinal pancreatic and…
- Trial name
- NCT03168594
- Testing
- irinotecan cisplatin, Etoposide cisplatin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)